Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Sponsored by

Logo 22.07.22.png
Patented Patent Copyright Law Business technology concept.

Anne Marie Clark, senior patent searcher at CAS, looks at ways to protect and commercialise the promise of RNAi

The value and complexity of the patent landscape around RNA interference (RNAi) is increasing, creating special challenges for patent searches to protect IP and maximise its value.

RNAi is claimed in a variety of ways within patents. Standard terminology is not always used, and chemical modifications can be described a variety of ways. These inconsistencies mean that there is no single search strategy that can be used to efficiently and comprehensively retrieve this information from different data sources.

Read an in-depth discussion of relevant challenges and search techniques for RNAi in this resource from CAS

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
SKW Schwarz partner Daniel Kendziur explains how new green claims rules are changing his workload and bringing him into direct contact with marketing, PR and government affairs teams
The government is targeting earlier resolution of SEP disputes while ruling out a standalone IPEC rate determination track and restrictions on injunctions
Gift this article